The present invention relates to a compound formula [I]:
1
wherein
R
1
is hydrogen or halogen,
R
2
is hydrogen or an amino protective group,
R
3
is hydrogen or lower alkyl,
X is bond, —CH
2
— or —O—, and
Y is
2
in which R
4
is lower alkoxycarbonyl,
3
in which R
5
is carboxy(lower)alkyl, etc.,
4
in which R
6
is hydroxy, etc., and so on,
or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
本发明涉及一种化合物公式[I]:
1
其中
R
1
为氢或卤素,
R
2
为氢或氨基保护基,
R
3
为氢或低碳基,
X为键,-CH
2
-或-O-,以及
Y为
2
其中R
4
为低碳氧羰基,
3
其中R
5
为羧基(低)烷基等,
4
其中R
6
为羟基等,等等,
或其盐。本发明的化合物[I]及其药学上可接受的盐对于预防和/或治疗尿频或尿失禁具有用处。
[EN] AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] DERIVES AMINOALCOOLIQUES ET LEUR UTILISATION COMME AGONISTES DE RECEPTEUR BETA-3 ADRENERGIQUE
申请人:FUJISAWA PHARMACEUTICAL CO
公开号:WO2004045610A1
公开(公告)日:2004-06-03
The present invention relates to a compound formula [I] or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
Photoinduced Palladium‐Catalyzed Negishi Cross‐Couplings Enabled by the Visible‐Light Absorption of Palladium–Zinc Complexes
作者:Irini Abdiaj、Lena Huck、José Miguel Mateo、Antonio de la Hoz、M. Victoria Gomez、Angel Díaz‐Ortiz、Jesús Alcázar
DOI:10.1002/anie.201808654
日期:2018.10
A visible‐light‐induced Negishicross‐coupling is enabled by the activation of a Pd0–Zn complex. With this photocatalytic method, the scope of deactivated aryl halides that can be employed in the Negishicoupling was significantly expanded. NMR experiments conducted in the presence and absence of light confirmed that the formation of the palladium–zinccomplex is key for accelerating the oxidative
The first successful synthesis of dl-cepharanthine (XXXI) was described. dl-Cepharanthine was isolated together with its diastereoisomer (XXX) and diastereoisomeric pair of the structural isomer (XXIX), which were anticipated to be formed by Bischler-Napieralski cyclization followed by reduction and N-methylation of the cyclobisamide (IVa) obtained via unambiguous route.